Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Citrate/heparin/taurolidine - CorMedix Pharmaceuticals

Next Previous
Drug Profile

Citrate/heparin/taurolidine - CorMedix Pharmaceuticals

Alternative Names: Citrate/taurolidine/heparin; CRMD 003; CRMD 004; Defencath; Heparin/citrate/taurolidine; Heparin/taurolidine/citrate; Neutrolin; Taurolidine/citrate/heparin; Taurolidine/heparin/citrate

Latest Information Update: 18 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ND Partners
  • Developer CorMedix
  • Class Alkanesulfonic acids; Antibacterials; Anticoagulants; Antifungals; Citrates; Heparins; Small molecules; Thiadiazines
  • Mechanism of Action Cell adhesion molecule inhibitors; Deoxyribonuclease 1 stimulants; Factor Xa inhibitors; Heparanase inhibitors; Inflammation mediator inhibitors; Lipopolysaccharide inhibitors; Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Catheter infections

Most Recent Events

  • 12 Mar 2024 CorMedix plans a post-approval meeting to discuss clinical pathway of DefenCath® for an expanded label with the US FDA in mid-year 2024
  • 08 Jan 2024 CorMedix plans to launch DefenCath for Catheter infections (Prevention) in USA by April 15, 2024 for the inpatient setting, and no sooner than July 1, 2024 for the outpatient setting
  • 15 Nov 2023 Registered for Catheter infections (Prevention) in USA (unspecified route)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top